Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $7.4 million.

  • Vivos Therapeutics' Total Current Liabilities rose 4508.39% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year increase of 4508.39%. This contributed to the annual value of $5.0 million for FY2024, which is 3170.53% down from last year.
  • Vivos Therapeutics' Total Current Liabilities amounted to $7.4 million in Q3 2025, which was up 4508.39% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Total Current Liabilities registered a high of $9.3 million during Q2 2021, and its lowest value of $4.7 million during Q1 2025.
  • For the 5-year period, Vivos Therapeutics' Total Current Liabilities averaged around $7.0 million, with its median value being $7.2 million (2023).
  • Data for Vivos Therapeutics' Total Current Liabilities shows a peak YoY increase of 4508.39% (in 2025) and a maximum YoY decrease of 4174.72% (in 2025) over the last 5 years.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Total Current Liabilities stood at $7.5 million in 2021, then dropped by 9.27% to $6.8 million in 2022, then increased by 6.99% to $7.3 million in 2023, then tumbled by 31.71% to $5.0 million in 2024, then skyrocketed by 49.4% to $7.4 million in 2025.
  • Its Total Current Liabilities stands at $7.4 million for Q3 2025, versus $6.4 million for Q2 2025 and $4.7 million for Q1 2025.